CN101801936B - 安立生坦的代谢物和衍生物 - Google Patents

安立生坦的代谢物和衍生物 Download PDF

Info

Publication number
CN101801936B
CN101801936B CN2008801071505A CN200880107150A CN101801936B CN 101801936 B CN101801936 B CN 101801936B CN 2008801071505 A CN2008801071505 A CN 2008801071505A CN 200880107150 A CN200880107150 A CN 200880107150A CN 101801936 B CN101801936 B CN 101801936B
Authority
CN
China
Prior art keywords
ambrisentan
metabolites
metabolite
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801071505A
Other languages
English (en)
Chinese (zh)
Other versions
CN101801936A (zh
Inventor
L·S·小麦尔温
M·尤尔里奇
H-G·海格
J·维曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Co ltd
Gilead Colorado Inc
Original Assignee
Albert Co ltd
Gilead Colorado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Co ltd, Gilead Colorado Inc filed Critical Albert Co ltd
Publication of CN101801936A publication Critical patent/CN101801936A/zh
Application granted granted Critical
Publication of CN101801936B publication Critical patent/CN101801936B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CN2008801071505A 2007-07-31 2008-07-31 安立生坦的代谢物和衍生物 Expired - Fee Related CN101801936B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95305307P 2007-07-31 2007-07-31
US60/953,053 2007-07-31
PCT/US2008/009236 WO2009017777A2 (en) 2007-07-31 2008-07-31 Metabolites and derivatives of ambrisentan

Publications (2)

Publication Number Publication Date
CN101801936A CN101801936A (zh) 2010-08-11
CN101801936B true CN101801936B (zh) 2012-10-03

Family

ID=39924953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801071505A Expired - Fee Related CN101801936B (zh) 2007-07-31 2008-07-31 安立生坦的代谢物和衍生物

Country Status (8)

Country Link
US (1) US8217155B2 (enExample)
EP (1) EP2183223A2 (enExample)
JP (1) JP2010535210A (enExample)
CN (1) CN101801936B (enExample)
AU (1) AU2008282773B8 (enExample)
CA (1) CA2695259C (enExample)
MX (1) MX2010001255A (enExample)
WO (1) WO2009017777A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
ES2544724T3 (es) 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
ES2627944T3 (es) 2010-10-15 2017-08-01 Gilead Sciences, Inc. Composiciones y métodos de tratamiento de hipertensión pulmonar
CN102276536B (zh) 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN103012281B (zh) * 2011-09-22 2015-04-08 江苏康缘药业股份有限公司 一种手性2-[(4,6-二甲基嘧啶-2-基)氧基]-3-甲氧基-3,3-二苯基丙酸的消旋化方法
CN104280480B (zh) * 2013-07-02 2016-12-28 天津药物研究院有限公司 一种分离检测安立生坦及其有关物质的方法
CN104515816B (zh) * 2013-09-29 2016-04-20 天津药物研究院 一种安立生坦原料及制剂有关物质的检测方法
CN104359993B (zh) * 2014-12-09 2016-03-30 江苏康缘药业股份有限公司 一种安立生坦有关物质的检测方法
EP3235496A1 (en) * 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
CN116327758A (zh) 2019-12-17 2023-06-27 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19726146A1 (de) * 1997-06-19 1998-12-24 Basf Ag Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
PA8652001A1 (es) * 2004-11-05 2006-10-13 Wyeth Corp Metabolitos glucuronidos de tigeciclina y epimeros de los mismos
DE602006007210D1 (de) * 2005-01-25 2009-07-23 Dompe Pha R Ma Spa Res & Mfg Metaboliten aus 2-arylpropionsäure-derivaten und pharmazeutische zusammensetzungen damit
KR101390563B1 (ko) * 2005-01-31 2014-04-30 밀란 인크. 글루쿠로니드화된 네비볼롤
WO2006136945A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS
EP2091539A1 (en) 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
ES2544724T3 (es) * 2006-12-12 2015-09-03 Gilead Sciences, Inc. Composición para tratar una hipertensión pulmonar
CA2695259C (en) 2007-07-31 2016-05-24 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
CA2904447C (en) * 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19726146A1 (de) * 1997-06-19 1998-12-24 Basf Ag Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten

Also Published As

Publication number Publication date
AU2008282773B2 (en) 2012-11-08
MX2010001255A (es) 2010-12-06
EP2183223A2 (en) 2010-05-12
AU2008282773B8 (en) 2013-03-07
CA2695259C (en) 2016-05-24
US8217155B2 (en) 2012-07-10
US20100204163A1 (en) 2010-08-12
CN101801936A (zh) 2010-08-11
WO2009017777A3 (en) 2009-04-09
CA2695259A1 (en) 2009-02-05
WO2009017777A2 (en) 2009-02-05
AU2008282773A1 (en) 2009-02-05
JP2010535210A (ja) 2010-11-18

Similar Documents

Publication Publication Date Title
CN101801936B (zh) 安立生坦的代谢物和衍生物
CN109721527B (zh) 一种新型抗pd-l1化合物、其应用及含其的组合物
KR102365535B1 (ko) 2,6-디아미노 피리딘 화합물
WO2017129116A1 (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
US12240849B2 (en) Nitrogen-containing spiro derivative as RET inhibitor
CN107253933B (zh) 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途
US20110124704A1 (en) Deuterium-enriched atorvastatin
JP2018538355A (ja) ベンズアミド誘導体
ITMI991452A1 (it) Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica
Urabe et al. Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability
KR101386318B1 (ko) 히스타민 ｈ3 수용체의 길항제로서의 이소퀴놀린 및 벤조［ｈ］이소퀴놀린 유도체, 그의 제조 및 치료 용도
US12221432B2 (en) Estrogen receptor antagonist
WO2018006077A1 (en) Deuterated compounds for treating pain
WO2021169769A1 (zh) 芳香族化合物及其药物组合物和用途
RU2827863C2 (ru) Конденсированное трициклическое соединение в качестве двойного ингибитора pde3/pde4
HK40045261A (en) 2,6-diamino pyridine compounds
HK40045261B (en) 2,6-diamino pyridine compounds
EA040490B1 (ru) Соединения 2,6-диаминопиридина
HK40062570A (en) Estrogen receptor antagonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121003

Termination date: 20180731

CF01 Termination of patent right due to non-payment of annual fee